News coverage about Misonix (NASDAQ:MSON) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Misonix earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 48.0813001811164 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Misonix (NASDAQ MSON) traded up $0.05 on Thursday, hitting $9.75. The company’s stock had a trading volume of 2,882 shares, compared to its average volume of 5,485. The firm has a market cap of $90.85, a P/E ratio of -33.62 and a beta of 0.22. Misonix has a 1 year low of $7.05 and a 1 year high of $12.00.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.truebluetribune.com/2018/01/12/misonix-mson-receives-coverage-optimism-rating-of-0-10.html.
Misonix, Inc designs, manufactures, develops and markets minimally invasive therapeutic ultrasonic medical devices. The Company’s products include BoneScalpel surgical system (BoneScalpel), SonaStar Surgical Aspirator (SonaStar), and SonicOne Wound Cleansing and Debridement System (SonicOne). These devices primarily serve the neurosurgery, orthopedic surgery, plastic surgery, wounds, burn and maxillo-facial clinical specialties.
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.